Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which may reassure users when the therapies are in short supply.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Zepbound is a once-weekly injectable weight loss medication that contains tirzepatide as its active ingredient. In 2023, it was approved for use for chronic weight management in adults living with ...